Amarin (NASDAQ:AMRN) Lowered to Strong Sell Rating by Zacks Research

Amarin (NASDAQ:AMRN) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($2.93) EPS, FY2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($2.71) EPS, Q2 2026 earnings at ($2.55) EPS, Q3 2026 earnings at ($4.22) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($17.05) EPS, Q1 2027 earnings at ($2.77) EPS, Q2 2027 earnings at ($2.77) EPS, Q3 2027 earnings at ($3.33) EPS, Q4 2027 earnings at ($6.46) EPS and FY2027 earnings at ($15.33) EPS.

A number of other equities research analysts also recently weighed in on AMRN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amarin in a report on Wednesday, January 21st. Wall Street Zen downgraded Amarin from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. Three research analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Strong Sell” and an average price target of $12.00.

Amarin Stock Down 4.0%

AMRN stock opened at $15.07 on Tuesday. The company’s 50-day moving average price is $14.91 and its two-hundred day moving average price is $15.80. The firm has a market cap of $313.31 million, a P/E ratio of -6.05 and a beta of 0.72. Amarin has a 12 month low of $7.08 and a 12 month high of $20.90.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AMRN. Waterfront Wealth Inc. boosted its holdings in shares of Amarin by 82.8% during the 4th quarter. Waterfront Wealth Inc. now owns 142,540 shares of the biopharmaceutical company’s stock valued at $1,990,000 after acquiring an additional 64,580 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Amarin by 534.2% during the third quarter. JPMorgan Chase & Co. now owns 21,754 shares of the biopharmaceutical company’s stock valued at $356,000 after purchasing an additional 18,324 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Amarin by 1,816.7% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 5,450 shares during the last quarter. Millennium Management LLC increased its stake in shares of Amarin by 192.6% in the third quarter. Millennium Management LLC now owns 132,391 shares of the biopharmaceutical company’s stock valued at $2,169,000 after buying an additional 87,147 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in Amarin by 13.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,008 shares during the last quarter. 22.25% of the stock is currently owned by institutional investors.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.